KP136 (AL-136) is a potent, orally active anti-allergic agent; it inhibits histamine release and mast cell degranulation (IC₅₀ = 76.1 μg/mL and 63 μg/mL, respectively); it effectively suppresses mast cell activation in vitro in a dose-dependent manner; in vivo, it shows significant inhibitory effects on allergic responses, with oral administration (2 mg/kg) achieving ~66% inhibition, and intravenous administration (1 mg/kg) markedly inhibiting 5-h homologous passive cutaneous anaphylaxis (PCA), exhibiting activity comparable to that of C4C.